Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours.
Jason D LickliterMark VoskoboynikLinda MileshkinHui K GanGanessan KichenadasseKathy ZhangMaggie ZhangZhiyu TangMichael MillwardPublished in: British journal of cancer (2021)
NCT02361723.